PDS Biotech to Participate at BTIG Biotechnology Conference 2022

FLORHAM PARK, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune^® and Infectimune™ T cell activating technologies, today announced that its management will participate in a fireside chat and one-on-one meetings at the BTIG Biotechnology Conference, a hybrid event taking place August 8-9, 2022. 

To participate in the live event and schedule meetings with management, please contact your BTIG representative.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune^® and Infectimune™ T cell activating technology platforms. We believe our Versamune^® based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune^® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company continues to advance its pipeline of preclinical and clinical candidates to address a wide range of cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers. 

Our Infectimune™ based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses including long-lasting memory T cell responses. To learn more, please visit  or follow us on Twitter at @PDSBiotech.

Versamune^® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology Corporation.

Investor Contacts:

Deanne Randolph

PDS Biotech

Phone: +1 (908) 517-3613

Rich Cockrell

CG Capital

Phone: +1 (404) 736-3838